Current therapy in medicine of Australian mammals. L Vogelnest, T Portas (editors). CSIRO Publishing, 2019. 796 pages. Price A$220.00. ISBN 9781486307517.

Current Therapy in Medicine of Australian Mammals provides an update on Australian mammal medicine. Although much of the companion volume, Medicine of Australian Mammals, is still relevant and current, there have been significant advances in Australian mammal medicine and surgery since its publication in 2008. The two texts together remain the most comprehensive source of information available in this field. This volume is divided into two sections. The first includes comprehensive chapters on general topics and topics relevant to multiple taxa. Several new topics are presented including: wildlife health in Australia and the important role veterinarians play in Australia’s biosecurity systems; medical aspects of native mammal reintroductions and translocations; disease risk analysis; wildlife rehabilitation practices in Australia with an emphasis on welfare of animals undergoing rehabilitation; management of overabundant populations; immunology; and stress physiology. The second section provides updates on current knowledge relevant to specific taxa. Several appendices provide useful reference data and information on clinical reference ranges, recommended venipuncture sites, chemical restraint agent doses and regimens, a drug formulary and dental charts. Written by Australian experts, Current Therapy in Medicine of Australian Mammals is clinically oriented, with emphasis on practical content with easy-to-use reference material. It is a must-have for veterinarians, students, biologists, zoologists and wildlife carers and other wildlife professionals. This volume also complements, updates and utilises the resources of other books such as Radiology of Australian Mammals (Vogelnest and Allan 2015), Pathology of Australian Native Wildlife (Ladds 2009), Haematology of Australian Mammals (Clark 2004) and Australian Mammals: Biology and Captive Management (Jackson 2003), all CSIRO Publishing publications.

Download Full-text

Current Therapy in Medicine of Australian Mammals. Larry Vogelnest and Timothy Portas, editors.2019. CSIRO Publishing, Clayton South, Victoria, Australia. 796 pp. $168.00 hardcover. ISBN: 9781486307517

Journal of Wildlife Management ◽

10.1002/jwmg.21779 ◽

2019 ◽

Vol 84 (2) ◽

pp. 390-390

Author(s):

Phil Tucak

Keyword(s):

Current Therapy ◽

Csiro Publishing

Download Full-text

Current Therapy in Childhood Brain Tumors

Neurologic Clinics ◽

10.1016/s0733-8619(18)31060-0 ◽

1985 ◽

Vol 3 (1) ◽

pp. 147-164 ◽

Cited By ~ 5

Author(s):

Michael E. Cohen ◽

Patricia K. Duffner

Keyword(s):

Brain Tumors ◽

Current Therapy ◽

Childhood Brain Tumors

Download Full-text

Extravascular Administration of Factor IX: Potential for Replacement Therapy of Canine and Human Hemophilia B

Thrombosis and Haemostasis ◽

10.1055/s-0038-1656082 ◽

1997 ◽

Vol 77 (05) ◽

pp. 0944-0948 ◽

Cited By ~ 20

Author(s):

Darla Liles ◽

Charles N Landen ◽

Dougald M Monroe ◽

Celeste M Lindley ◽

Marjorie s Read ◽

...

Keyword(s):

Gene Therapy ◽

Vitamin K ◽

Absorption Rate ◽

Venous Access ◽

Factor Ix ◽

Hemophilia B ◽

Current Therapy ◽

Home Therapy ◽

Routes Of Administration ◽

Plasma Compartment

SummaryCurrent therapy for hemophilia B requires large intravenous doses of factor IX (F.IX) given in the clinic or at home. Although home therapy is possible for many patients, it is often complicated by factors such as the lack of good venous access. Very little is known about extravascular routes for administering proteins like F.IX (57 kD) or other vitamin K-dependent procoagulant factors into the circulation. Questions about the absorption rate from extravascular administration as well as plasma recovery and bioavailability have arisen recently with the growing availibility of highly purified procoagulant proteins and increased interest in gene therapy of hemophilia B. Therefore, a group of studies were undertaken to determine the absorption rate, plasma recovery, and bioavailability of high purity, human plasma-derived F.IX concentrates administered via extravascular routes in hemophilia B dogs and in one human hemophilia B subject. Five hemophilia B dogs were given human F.IX via either a subcutaneous (SC), intramuscular (IM), intra- peritoneal (IP) or intravenous (IV) route. In a subsequent study, a single SC administration of human F.IX was compared to an identical IV dose of F.IX in the human hemophilia B subject. All extravascular routes of F.IX administration in both the canine and human gave lower levels of circulating plasma F.IX than the IV route, however all routes resulted in measurable F.IX activity. Of the extravascular routes, the IM injection in the canine resulted in a bioavailibility of 82.8%, while the SC injection resulted in a bioavailability of 63.5%. F.IX reached the plasma compartment by all extravascular routes used, confirming that F.IX can be absorbed extravascularly. The duration of measurable F.IX activity following extravascular administration is prolonged beyond that typically seen with IV administration. These data show that significant levels of F.IX may be obtained via SC injection in canine and ‘ human hemophilia B subjects and further highlight the potential of extravascular routes of administration for future experimental and clinical uses of F.IX and other procoagulant proteins.

Download Full-text

Current Therapy in Hematology/Oncology

Pathology ◽

10.3109/00313028609087580 ◽

1986 ◽

Vol 18 (4) ◽

pp. 487

Author(s):

Roger D. Scurr

Keyword(s):

Current Therapy

Download Full-text

Current Therapy of Diabetic Macular Edema Bevacizumab, Triamcinolone Acetonide, and Laser Photocoagulation

Ophthalmologica Indonesiana ◽

10.35749/journal.v45i1.172 ◽

2019 ◽

Vol 45 (1) ◽

pp. 13

Author(s):

Gladys Kusumowidagdo ◽

Randy Sarayar ◽

Kartika Rahayu ◽

Gitalisa Andayani

Keyword(s):

Macular Edema ◽

Triamcinolone Acetonide ◽

Diabetic Macular Edema ◽

Systematic Reviews ◽

Laser Photocoagulation ◽

Meta Analysis ◽

Intravitreal Bevacizumab ◽

Current Therapy ◽

Intravitreal Triamcinolone ◽

Mesh Terms

Background: Diabetic macular edema (DME) is the main cause of visual impairment in diabetic retinopathy (DR). Current gold standard therapy of DME is macular laser photocoagulation (MPC). Growing evidences have shown benefits of intravitreal anti-VEGF agents (i.e bevacizumab) and intravitreal corticosteroids (i.e triamcinolone acetonide). Aim: To compare the visual acuity (VA) improvement of patients with DME, treated with intravitreal bevacizumab (IVB), a combination of IVB and intravitreal triamcinolone (IVB/IVT), and MPC. Method: A comprehensive PubMed® and Cochrane® databases search was conducted on May 4th, 2017 using appropriate keywords (diabetic macular edema, bevacizumab, triamcinolone, and laser photocoagulation using their MeSH terms). Studies were filtered using inclusion criterions (clinical trials, RCT, meta-analysis, systematic review, English, humans, and publication within 10 years) Results: Three studies (2 systematic reviews and 1 RCT) were found suitable. From these results, all studies showed favoring effects of IVB when compared to IVB/IVT combination and MPC in short term period (up to 6 months). However, there was no significant improvement of VA beyond this period in all groups. Conclusion: IVB appears to be superior to IVB/IVT and MPC in improving VA during 6 months follow- up period. Future systematic reviews and meta-analysis are required on the effect of IVB and MPC combination in cases of DME.

Download Full-text

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

Current Pharmaceutical Design ◽

10.2174/1381612826666201021130146 ◽

2020 ◽

Vol 26 ◽

Author(s):

Ritu Mishra ◽

Swati Gupta

Keyword(s):

Rheumatoid Arthritis ◽

Drug Delivery ◽

Autoimmune Disease ◽

Drug Delivery Systems ◽

Clinical Manifestations ◽

Adaptive Immune Response ◽

Delivery Systems ◽

Current Therapy ◽

Genetic And Environmental Factors ◽

Novel Drug

Background: Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. : The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal drugs in passive and receptor mediated active targeting against RA. On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.

Download Full-text

Towards Breast Cancer Vaccines, Progress and Challenges

Current Drug Discovery Technologies ◽

10.2174/1570163815666180502164652 ◽

2019 ◽

Vol 16 (3) ◽

pp. 251-258 ◽

Cited By ~ 3

Author(s):

Javad Behravan ◽

Atefeh Razazan ◽

Ghazal Behravan

Keyword(s):

Breast Cancer ◽

Adverse Effects ◽

Cancer Vaccine ◽

Cancer Vaccines ◽

Weight Control ◽

The Body ◽

Phase Iii ◽

Current Therapy ◽

Surgical Ablation ◽

Breast Cancer Vaccine

Breast cancer is the second leading cause of cancer death among women. National cancer institute of the US estimates that one in eight women will be diagnosed with breast cancer during their lifetime. Considering the devastating effects of the disease and the alarming numbers many scientists and research groups have devoted their research to fight breast cancer. Several recommendations are to be considered as preventing measures which include living a healthy lifestyle, regular physical activity, weight control and smoking cessation. Early detection of the disease by annual and regular mammography after the age of 40 is recommended by many healthcare institutions. This would help the diagnosis of the disease at an earlier stage and the start of the treatment before it is spread to other parts of the body. Current therapy for breast cancer includes surgical ablation, radiotherapy and chemotherapy which is often associated with adverse effects and even may lead to a relapse of the disease at a later stage. In order to achieve a long-lasting anticancer response with minimal adverse effects, development of breast cancer vaccines is under investigation by many laboratories. The immune system can be stimulated by a vaccine against breast cancer. This approach has attracted a great enthusiasm in recent years. No breast cancer vaccines have been approved for clinical use today. One breast cancer vaccine (NeuVax) has now completed clinical trial phase III and a few preventive and therapeutic breast cancer vaccines are at different steps of development. We think that with the recent advancements in immunotherapy, a breast cancer vaccine is not far from reach.

Download Full-text

Novel Scaffolds for Leishmania infantum Trypanothione Reductase Inhibitors Derived from Brazilian Natural Products Biodiversity

Anti-Infective Agents ◽

10.2174/2211352518666200131121308 ◽

2021 ◽

Vol 18 (4) ◽

pp. 398-418

Author(s):

Vinícius Guimarães da Paixão ◽

Samuel Silva da Rocha Pita

Keyword(s):

Natural Products ◽

Leishmania Infantum ◽

In Vitro Assays ◽

Current Therapy ◽

Pharmacokinetic Analysis ◽

Trypanothione Reductase ◽

Resistant Species ◽

Reductase Inhibitors ◽

Thiol Redox

Background: Leishmania infantum causes the most lethal form of Leishmaniasis: Visceral leishmaniasis. Current therapy for this disease is related to the development of drug-resistant species and toxicity. Trypanothione Reductase (LiTR), a validated target for the drug discovery process, is involved with parasites' thiol-redox metabolism. Objective: In this study, through Virtual Screening employing two distinct Natural Products Brazilian databases, we aimed to identify novel inhibitor scaffolds against LiTR. Results: Thus, the “top 10” LiTR-ligand energies have been selected and their interaction profiles into LiTR sites through the AuPosSOM server have been verified. Finally, Pred-hERG, Aggregator Advisor, FAF-DRUGS, pkCSM and DataWarrior were employed and their results allowed us to evaluate, respectively, the cardiotoxicity, aggregation capacity, presence of false-positive compounds (PAINS) and their toxicities. Conclusion: Three molecules that overcame the in silico pharmacokinetic analysis and have a good interaction with LiTR, were chosen to use in vitro assays hoping that our computational results reported here would aid the development of new anti-leishmanial compounds.

Download Full-text